[G25-12] Fosdenopterin (molybdenum cofactor deficiency Type A) – Assessment according to §35a (para. 1, sentence 11) Social Code Book V
Last updated 11.06.2025
Project no.:
G25-12
Commission:
Commission awarded on 13.03.2025 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission work started
Department/Division:
Health Economics
Topic:
Head and nerves
Note:
In accordance with §35a (1) Sentence 11 Social Code Book (SGB) V, the added medical benefit of orphan drugs is deemed as proven by the fact that they have been approved. On behalf of the Federal Joint Committee (G-BA), IQWiG therefore solely assesses the information on patient numbers and costs in the pharmaceutical company's dossier.